An Exciting Time for Research into CTEPH Discussed in Review Article

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis can become lodged in blood vessels leading to the lungs and occlude blood flow. Individuals without any history of pulmonary embolisms are susceptible to CTEPH, making it important to understand the pathophysiology, risks factors, and signs of CTEPH.

 

As suggested by a recent review entitled, “Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism,” which was published in Current Cardiology Reports, it is an exciting time for researchers in the field of CTEPH and patients who suffer from the disease. A lot of progress has been made in understanding CTEPH, leading to better diagnosis techniques and therapeutic options.

“Although it is generally believed that CTEPH originates with acute venous thromboembolism, interestingly, up to 40% of CTEPH patients will have no antecedent history suggestive of acute pulmonary embolism,” wrote Dr. Alison S. Witkin and Dr. Richard N. Channick, of the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital in Boston.

Often times, CTEPH symptoms are confused with those of other cardiac and pulmonary diseases, which can lead to delays between first notice of symptoms and CTEPH diagnosis. Shortness of breath, progressive exercise intolerance, and chest pain are all indicators of some form of pulmonary hypertension. However, a large difference between pulmonary arterial hypertension and CTEPH is the type of blood vessels that are affected. Pulmonary arterial hypertension affects blood vessels smaller than 300 micrometers in size, while CTEPH affects larger blood vessels that are closer to the heart.

Since patients and their clinicians may not suspect CTEPH is the root cause of symptoms due to the disconnect between patient history and the ease of coming to an improper diagnose, it is important to have a standard technique to diagnose CTEPH. Commonly, ventilation perfusion scans are used to suggest CTEPH, but the gold standard to properly diagnose CTEPH is via right heart catheterization and pulmonary artery angiogram. These may be performed when patients have the indicative symptoms for CTEPH and have some of the common risk factors: idiopathic pulmonary embolism, large perfusion defects, and a right ventricular systolic pressure greater than 50 mmHg.

Once properly diagnosed, CTEPH, unlike other forms of pulmonary hypertension, can be cured by the surgical procedure known as pulmonary thromboendarterectomy (PTE). Recently, a medication developed by Bayer, Adempas (riociguat), was approved by the Food and Drug Administration for patients with CTEPH. Adempas is also indicated for pulmonary arterial hypertension, as the drug acts to increase vessel diameter to allow blood to flow more easily, reducing the pressure the heart must work against to pump blood to the lungs.

Because there are viable treatment options for those with CTEPH, the most significant unmet medical need for addressing the disease is improving early detection, since patient outcomes are hinged on how early an accurate CTEPH diagnosis is made. With researchers making substantial progress in improving early detection of CTEPH, the medical community is becoming increasingly capable of treating and curing people with the disease.

Comment

  • BrozovTex BrozovTex Thursday, 02 July 2015

    what is normal dose of cialis

    cialis

    buy cialis

    where buy cialis

  • BrozovTex BrozovTex Thursday, 02 July 2015

    i recommend cialis india

    cialis online

    cialis cheap

    buy cheap cialis on line

  • NataTex NataTex Thursday, 02 July 2015

    cialis generique gratuit

    buy cialis online

    tadalafil

    buy cialis in usa overnight

  • StedyTex StedyTex Thursday, 02 July 2015

    best viagra name in india

    buy viagra online

    online viagra

    viagra espana precio

  • NataTex NataTex Thursday, 02 July 2015

    cialis rezeptfrei kaufen wo.

    cialis canada

    tadalafil

    cialis soft tab for sale

  • BrozovTex BrozovTex Thursday, 02 July 2015

    cialis south africa online

    cheap cialis

    cheap cialis

    preis cialis 20mg 4 stck

  • StedyTex StedyTex Thursday, 02 July 2015

    just try! china viagra

    buy viagra

    online viagra

    acheter viagra dhea

  • NataTex NataTex Thursday, 02 July 2015

    cialis tem generico

    buy canadian cialis

    buy cialis

    cialis made in usa

  • BrozovTex BrozovTex Thursday, 02 July 2015

    buy cialis 5mg lowest price

    generic cialis

    cialis generic

    genericos cialis super active

  • BrozovTex BrozovTex Thursday, 02 July 2015

    buy cialis miami

    cialis price

    cialis online

    el cialis compro barato

Leave your comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

About Us

The Saudi Association for Pulmonary Hypertension (SAPH) is a medical and research national group of many medical specialists, who shared a common interest in the field of pulmonary vascular disease. The main goal for SAPH is to increase the awareness and the knowledge of pulmonary vascular diseases in the society and between the medical professionals.

The Saudi Association for Pulmonary Hypertension (SAPH) is a Subsidiary of The

Saudi Association for PH

STS office (Exit 11 & the Airport Road)

Riyadh, Saudi Arabia

P. O. Box 106911
Riyadh 11676
Saudi Arabia

Tel:+966-11-2488966
Fax: +966-11-2487431
Mobile:+966506426704

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…